Drug intelligence / Profile preview

Lactobacillus paracasei KKA394

Development stage: Preclinical
Lead developer: The University of Hong Kong
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

*Lactobacillus paracasei* KKA394 is a specific strain of probiotic bacteria investigated as a live biotherapeutic delivery vehicle for therapeutic proteins. In research contexts, it has been genetically engineered to express and secrete a pentameric analogue of Glucagon-like peptide-1 (GLP-1) for the treatment of type 2 diabetes. The strain is designed to deliver the GLP-1 analogue in situ to the intestinal mucosa, where it is cleaved by endogenous trypsins into an active monomeric form. This active GLP-1 then stimulates insulin secretion from pancreatic cells in a glucose-dependent manner. While the strain itself has demonstrated intrinsic glucose-lowering properties in diabetic GK (Goto-Kakizaki) rat models, the engineered version aims to provide a sustained insulinotropic effect to normalize blood glucose levels.

Other names: L. paracasei KKA394

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on Lactobacillus paracasei KKA394.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus paracasei KKA394.

Explore the full profile